BiotechTubeBiotechTube
Home/Pipeline/KHK4083

KHK4083

Atopic dermatitis

Phase 2Active

Key Facts

Indication
Atopic dermatitis
Phase
Phase 2
Status
Active
Company
Kyowa Kirin

About Kyowa Kirin

Kyowa Kirin is a leading specialty pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on rare diseases and oncology. The company has built a robust pipeline through internal R&D capabilities and strategic partnerships, with particular expertise in antibody engineering and cell therapy technologies. Kyowa Kirin operates globally with a presence in Japan, Asia-Pacific, North America, and Europe, and is publicly traded on the Tokyo Stock Exchange.

View full company profile

Therapeutic Areas

Rare DiseasesOncologyImmunologyNephrologyHematology

Other Atopic dermatitis Drugs

DrugCompanyPhase
LebrikizumabEli LillyPhase 3
DupixentSanofiCommercial
ASP2408Astellas PharmaPhase 2
KW-6356Kyowa KirinPhase 2
Opzelura (ruxolitinib cream)Ono PharmaceuticalApproved
ONO-7913Ono PharmaceuticalPhase 2
KT-474Kymera TherapeuticsPhase 2
GRC 27864Glenmark PharmaceuticalsPhase 2
ARQ-234Arcutis BiotherapeuticsPreclinical/Phase 1
STAR-0310BioCryst PharmaceuticalsPhase 1
RezpegaldesleukinNektar TherapeuticsPhase 2b
ZL-1503Zai LabPhase (Early Clinical)